Tirzepatide
Tirzepatide
The next-generation dual-agonist delivering superior weight loss to Semaglutide in clinical trials.
Medical Disclaimer: The information on this page is for educational purposes only and does not constitute medical advice. Peptides discussed may be research compounds not approved for human use. Always consult a qualified healthcare provider before starting any peptide protocol. Read our full disclaimer →
Quick Reference
| Peptide Class | Dual GIP/GLP-1 Receptor Agonist |
| Half-Life | ~5 days |
| Administration | Subcutaneous injection (weekly) |
| Typical Dosage | 2.5 mg/week (starting), titrating to 5–15 mg/week |
| Cycle Length | Ongoing — typically 16–72 weeks in trials |
| Evidence Level | Strong Human Clinical |
| Legal Status | FDA-approved (Mounjaro for T2D, Zepbound for obesity) — requires prescription |
| Approximate Cost | $250–$1,300/month (brand); $175–$450/month (compounded via telehealth) |
How Tirzepatide Works
Activates both GIP and GLP-1 receptors, producing additive effects on appetite suppression, insulin secretion, and fat mobilization.
Tirzepatide is the first approved dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptor agonist. By activating both receptors simultaneously, it produces additive effects on appetite suppression, insulin secretion, and fat mobilization. GIP receptor activation appears to enhance the GLP-1-mediated effects on adipose tissue, potentially explaining Tirzepatide's superior weight loss outcomes compared to GLP-1-only agonists like Semaglutide.
Evidence Base
Preclinical Evidence
Animal studies demonstrate superior weight loss and metabolic improvements compared to GLP-1 monotherapy.
Human Evidence
The SURPASS and SURMOUNT trial programs demonstrate average weight loss of 15–22.5% at the highest doses — significantly exceeding Semaglutide's 10–15% in head-to-head comparisons. The SURMOUNT-1 trial showed 22.5% weight loss at 72 weeks with 15 mg Tirzepatide.
Anecdotal Evidence
Users who have tried both Semaglutide and Tirzepatide consistently report greater weight loss and appetite suppression with Tirzepatide. Side effect profiles are similar, though some users report better GI tolerability with Tirzepatide.
Key PubMed References:
Safety Profile
Side Effects
Similar to Semaglutide: nausea, vomiting, diarrhea, constipation. Generally similar or slightly better GI tolerability than Semaglutide in clinical trials.
Contraindications
Same as Semaglutide: personal/family history of medullary thyroid carcinoma, MEN2, active pancreatitis, pregnancy.
PeptidePilot Assessment
Tirzepatide is PeptidePilot's recommendation for users who want maximum weight loss efficacy and are willing to accept a newer compound with a shorter (but still robust) clinical track record. In our algorithm, users who score very high on the fat loss and metabolic domains and have not responded adequately to other interventions are preferentially matched to Tirzepatide over Semaglutide.
📊 Included in the 28% of users who receive the Semaglutide/Tirzepatide category as their top match
Frequently Asked Questions
Explore More Peptides
The most researched healing peptide for joints, tendons, and gut tissue.
Systemic tissue repair and anti-inflammatory recovery for athletes and injury rehabilitation.
The cleanest growth hormone secretagogue for muscle growth, fat loss, and sleep quality.
Extended-release GHRH analogue that amplifies and sustains growth hormone pulses.
The clinically established GHRH analogue with the longest safety record in anti-aging medicine.
The most clinically validated peptide for weight loss and metabolic health.